Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women.

Eur J Obstet Gynecol Reprod Biol

Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Hippokration General Hospital, 93 Plastira Str., Aretsou, 55132 Thessaloniki, Greece.

Published: February 2005

This is a preliminary study investigating the efficacy of aromatase inhibitor anastrozole in treating endometrial hyperplasia in obese postmenopausal women. We administered anastrozole for 12 months to 11 obese postmenopausal women with high operative risk, in order to treat endometrial hyperplasia (four simple, five complex and two atypical). Endometrial thickness in all cases and histology too in the two cases with atypia, revealed atrophical endometrium during treatment and additional mean follow-up of 10.2 months. The safety and tolerance profile was satisfactory. Anastrozole appears to be an interesting new modality for the treatment of endometrial hyperplasia in obese postmenopausal women.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejogrb.2004.07.002DOI Listing

Publication Analysis

Top Keywords

endometrial hyperplasia
16
obese postmenopausal
16
postmenopausal women
16
hyperplasia obese
12
aromatase inhibitor
8
inhibitor anastrozole
8
anastrozole treating
8
treating endometrial
8
endometrial
5
anastrozole
4

Similar Publications

In dogs, the characterization of intraluminal uterine contents has been subjectively carried out by the operators. The aims of this study were: 1) To ultrasonographically describe and compare the echogenicity and heterogeneity of the intraluminal uterine contents in bitches using digital analysis; 2) To assess the cytology of the uterine contents; 3) To evaluate the effect of clinical, ultrasonographic, bacteriological and cytological parameters on intraluminal contents echogenicity and heterogeneity. Twenty-one intact, 3-24 kg, 1-12 years of age, female dogs with ultrasonographically detected uterine content were included.

View Article and Find Full Text PDF

Introduction: This study evaluated the safety and tolerability of fezolinetant in women with vasomotor symptoms (VMS) due to menopause in a pooled analysis of data from three 52-week phase 3 studies (SKYLIGHT 1, 2, and 4).

Methods: SKYLIGHT 1 and 2 were double-blind, placebo-controlled studies where women (≥ 40 to ≤ 65 years), with moderate to severe VMS (minimum average ≥ 7 hot flashes/day) were randomized to once-daily placebo, fezolinetant 30 mg or 45 mg. After 12 weeks, those on placebo were re-randomized to fezolinetant 30 mg or 45 mg, while those on fezolinetant continued on their assigned dose for 40 weeks.

View Article and Find Full Text PDF

PATHOMORPHOLOGICAL AND CLINICAL CHARACTERISTICS OF THE UTERUS IN COMBINED ADENOMYOSIS AND MYOMA.

Georgian Med News

October 2024

Azerbaijan Medical University, Department of Obstetrics and Gynecology II, Baku, Azerbaijan.

The Aim Of The Study: to examine the pathomorphological and clinical characteristics of the uterus in the combined form of fibroids and adenomyosis.

Methods: The research work was conducted within the framework of the scientific program of the Department of Obstetrics and Gynecology II at Azerbaijan Medical University for the years 2021-2024. In the course of this study, a comprehensive clinical, laboratory, and instrumental prospective examination was conducted on 113 patients aged 30 to 50 years (mean age 42,0±1,8 years) with combined adenomyosis and uterine fibroids.

View Article and Find Full Text PDF

Introduction: Appendiceal endometriosis (AE) is a rare condition, with a prevalence ranging from 0.05 % to 1.7 % in patients with endometriosis.

View Article and Find Full Text PDF

Objective: Aim: Investigation of hyperproliferative diseases of the female genital organs as a consequence of mixed urogenital infections.

Patients And Methods: Materials and Methods: The study included 56 women of reproductive age who experienced discomfort in the external genital area in the form of excessive vaginal discharge and/or unpleasant odour of the discharge, itching in the external genital area (main group). The control group consisted of 30 somatically and gynaecologically healthy patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!